secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2023-12-04T23:59:59+00:00
Accession:  0000950170-23-067468
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint reports positive Phase 2 DAVIO 2 topline for EYP-1901 in wet AMD; all endpoints met
--------------------------------------------------------------------------------

- Both EYP-1901 doses (2mg and 3mg) achieved non-inferiority in BCVA vs aflibercept (difference of -0.3 and -0.4 letters).
- Over 80% reduction in treatment burden; 65%/64% of eyes supplement-free up to six months for 2mg/3mg.
- No EYP-1901-related ocular or systemic SAEs; favorable safety profile.
- Phase 3 pivotal trial for wet AMD planned for H2 2024; DME trial starts Q1 2024; NPDR data Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017023067468/0000950170-23-067468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017023067468/eypt-20231204.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-067468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer